Galapagos NV - American Depositary Shares (GLPG)
27.39
+0.61 (2.26%)
NASDAQ · Last Trade: May 2nd, 9:59 AM EDT
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
Via Newsfile · May 30, 2024

- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers
By Frontier Medicines · Via GlobeNewswire · February 22, 2024